| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
General Counsel
1 company
Miller Edward is a General Counsel at Kalaris Therapeutics, Inc.. Recent SEC Form 4 filings include 0 buys and 13 sells.
Estimated insider holdings value: $34K based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 21, 2025 | KLRS Kalaris Therapeutics, Inc. | General Counsel | Sell | 106 | $10.08 | $1,068.03 | -1.6% | -70.6% | +3.8% | |
| Jan 23, 2025 | KLRS Kalaris Therapeutics, Inc. | General Counsel | Sell | 52 | $9.50 | $494.03 | -0.4% | -31.2% | -3.8% | |
| Jan 10, 2025 | KLRS Kalaris Therapeutics, Inc. | General Counsel | Sell | 409 | $0.44 | $180.00 | -0.3% | -27.6% | -3.2% | |
| Nov 19, 2024 | KLRS Kalaris Therapeutics, Inc. | General Counsel | Sell | 432 | $0.55 | $236.95 | -0.2% | -25.6% | -48.1% | |
| Nov 5, 2024 | KLRS Kalaris Therapeutics, Inc. | General Counsel | Sell | 2,272 | $0.86 | $1,965.05 | -1.1% | -57.0% | -78.0% | |
| Oct 22, 2024 | KLRS Kalaris Therapeutics, Inc. | General Counsel | Sell | 1,401 | $0.77 | $1,082.80 | -0.3% | -47.6% | -75.5% | |
| Oct 3, 2024 | KLRS Kalaris Therapeutics, Inc. | General Counsel | Sell | 377 | $0.81 | $307.18 | -0.2% | -45.0% | -64.7% | |
| Aug 19, 2024 | KLRS Kalaris Therapeutics, Inc. | General Counsel | Sell | 422 | $0.76 | $320.51 | -0.2% | -24.6% | -85.4% | |
| Aug 5, 2024 | KLRS Kalaris Therapeutics, Inc. | General Counsel | Sell | 2,323 | $0.73 | $1,706.94 | -1.1% | +21.3% | -84.8% | |
| Jul 22, 2024 | KLRS Kalaris Therapeutics, Inc. | General Counsel | Sell | 1,391 | $0.74 | $1,035.14 | -0.3% | +2.2% | -85.3% |